CD274 and acute myeloid leukemia: These data are consistent with clinical data from primary AML samples and suggest that 5-Aza treatment may increase activation of T-cells initially, but simultaneous hypomethylation of PD-1 and PD-L1 could lead to dampened immune responses shortly after.